179 related articles for article (PubMed ID: 35945130)
21. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
[TBL] [Abstract][Full Text] [Related]
22. Antibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis.
Fusco NM; Toussaint KA; Prescott WA
Ann Pharmacother; 2015 Apr; 49(4):458-68. PubMed ID: 25583881
[TBL] [Abstract][Full Text] [Related]
23. Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis.
VanDevanter DR; Heltshe SL; Hilliard JB; Konstan MW
J Cyst Fibros; 2021 Mar; 20(2):257-263. PubMed ID: 32505525
[TBL] [Abstract][Full Text] [Related]
24. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2008 Jul; (3):CD006961. PubMed ID: 18646176
[TBL] [Abstract][Full Text] [Related]
25. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
[TBL] [Abstract][Full Text] [Related]
26. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB
Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109
[TBL] [Abstract][Full Text] [Related]
27. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
Smith S; Ratjen F; Remmington T; Waters V
Cochrane Database Syst Rev; 2020 May; 5(5):CD006961. PubMed ID: 32412092
[TBL] [Abstract][Full Text] [Related]
28. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD006961. PubMed ID: 28628280
[TBL] [Abstract][Full Text] [Related]
29. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Greally P; Whitaker P; Peckham D
Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
[TBL] [Abstract][Full Text] [Related]
30. Oral anti-pseudomonal antibiotics for cystic fibrosis.
Remmington T; Jahnke N; Harkensee C
Cochrane Database Syst Rev; 2013 Oct; (10):CD005405. PubMed ID: 24170644
[TBL] [Abstract][Full Text] [Related]
31. Application of multiple event analysis as an alternative approach to studying pulmonary exacerbations as an outcome measure.
Juarez-Colunga E; Rosenfeld M; Zemanick ET; Wagner B
J Cyst Fibros; 2020 Jan; 19(1):114-118. PubMed ID: 30642785
[TBL] [Abstract][Full Text] [Related]
32. Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa.
Parkins MD; Rendall JC; Elborn JS
Chest; 2012 Feb; 141(2):485-493. PubMed ID: 21835906
[TBL] [Abstract][Full Text] [Related]
33. The effect of Pseudomonas aeruginosa eradication regimens on chronic colonization and clinical outcomes in pediatric patients with cystic fibrosis.
Nayir Buyuksahin H; Yalçın E; Emiralioglu N; Hazırolan G; Ademhan Tural D; Ozsezen B; Sunman B; Guzelkas I; Dogru D; Ozcelik U; Kiper N
Pediatr Int; 2022 Jan; 64(1):e15249. PubMed ID: 36321341
[TBL] [Abstract][Full Text] [Related]
34. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
[TBL] [Abstract][Full Text] [Related]
35. Oral anti-pseudomonal antibiotics for cystic fibrosis.
Remmington T; Jahnke N; Harkensee C
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD005405. PubMed ID: 27412131
[TBL] [Abstract][Full Text] [Related]
36. Are antipseudomonal antibiotics really beneficial in acute respiratory exacerbations of cystic fibrosis?
Wolter JM; Bowler SD; McCormack JG
Aust N Z J Med; 1999 Feb; 29(1):15-21. PubMed ID: 10200808
[TBL] [Abstract][Full Text] [Related]
37. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Langton Hewer SC; Smyth AR
Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria.
Castner LM; Zimbric M; Cahalan S; Powell C; Caverly LJ
J Cyst Fibros; 2021 Nov; 20(6):926-931. PubMed ID: 33612403
[TBL] [Abstract][Full Text] [Related]
39. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
[TBL] [Abstract][Full Text] [Related]
40. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations.
Zemanick ET; Harris JK; Wagner BD; Robertson CE; Sagel SD; Stevens MJ; Accurso FJ; Laguna TA
PLoS One; 2013; 8(4):e62917. PubMed ID: 23646159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
